A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity

The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector and an HIV envelope protein with alum, as shown in the RV144 trial. Since the efficacy was weak, and previous HIV vaccine trials designed to generate antibody responses fai...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Pattacini, Laura, Mize, Gregory J., Graham, Jessica B., Fluharty, Tayler R., Graham, Tisha M., Lingnau, Karen, Wizel, Benjamin, Perdiguero, Beatriz, Esteban, Mariano, Pantaleo, Giuseppe, Shen, Mingchao, Spies, Gregory A., McElrath, M. Juliana, Lund, Jennifer M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2012
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3405041/
https://ncbi.nlm.nih.gov/pubmed/22848738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0042163
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller